DOV Pharmaceutical, Significant Body Weight and BMI Reductions in Drug-Compliant Subjects in Phase Ib Clinical Study

Sept. 25 , 2007- DOV Pharmaceutical, Inc. announced additional Phase Ib results for DOV 21,947, its lead triple reuptake inhibitor ("TRIP") for the treatment of depression and obesity... DOV Pharmaceutical's Press Release -